<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834388</url>
  </required_header>
  <id_info>
    <org_study_id>NL76607.091.21</org_study_id>
    <nct_id>NCT04834388</nct_id>
  </id_info>
  <brief_title>Studying Anakinra to Reduce Secondary Brain Damage After Spontaneous Haemorrhagic Stroke</brief_title>
  <acronym>ACTION</acronym>
  <official_title>Anakinra in Cerebral Haemorrhage to Target Secondary Injury Resulting From Neuroinflammation - a Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous intracerebral haemorrhage (sICH) is the deadliest stroke subtype yearly affecting&#xD;
      over 6000 patients in the Netherlands. Treatment options are very limited. Inflammation plays&#xD;
      a vital role in the development of sICH-related secondary brain injury (SBI). Within 4 hours&#xD;
      after sICH onset, blood components and thrombin induce the release of cytokines and other&#xD;
      inflammatory molecules, with subsequent microglial activation, blood brain barrier (BBB)&#xD;
      damage and the formation of perihaematomal oedema (PHO). Among the released cytokines,&#xD;
      interleukin 1 beta (IL-1β) has a pivotal role. Recombinant human interleukin-1 receptor&#xD;
      antagonist (IL-1Ra, anakinra) effectively antagonizes IL-1β through competitive binding to&#xD;
      the IL-1 receptor. Anakinra is available for treatment of rheumatoid arthritis, other&#xD;
      inflammatory diseases and has been studied in acute sepsis. We hypothesize that anakinra&#xD;
      safely reduces SBI after sICH, and that is effect is dose-dependent.&#xD;
&#xD;
      Objective: To determine the effect of high-dose versus low-dose anakinra compared to standard&#xD;
      medical management on oedema extension distance (OED) determined with MRI on day 7±1. Second,&#xD;
      to study the safety profile of anakinra. Furthermore, to assess its effect on 1) serum&#xD;
      inflammatory markers IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts at day&#xD;
      1, 3 and 7 compared to baseline; 2) DCE-MRI measurement of BBB transfer constant (Ktrans) on&#xD;
      day 7±1, and; 3) to estimate an effect on functional outcome in patients with sICH.&#xD;
&#xD;
      Study design: Multicentre, prospective, randomized, three-armed (1:1:1) trial with open label&#xD;
      treatment and blinded end-point assessment (PROBE design) .&#xD;
&#xD;
      Study population: 75 patients with supratentorial sICH admitted within 8 hours after symptom&#xD;
      onset.&#xD;
&#xD;
      Intervention: Patients will receive anakinra in either a high dose (loading dose 500mg i.v.,&#xD;
      followed by infusion with 2mg/kg/h over 3 days; n=25) or in a low dose (loading dose 100mg&#xD;
      s.c.., followed by subcutaneous administration of 100mg twice a day for 3 days; n=25),&#xD;
      started within 8 hours of symptom onset. The control group (n=25) will receive standard&#xD;
      medical management.&#xD;
&#xD;
      Main study parameters/endpoints: Primary objective is to test whether anakinra reduces&#xD;
      subacute perihaematomal oedema after sICH, measured as OED on MRI at day 7±1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>PROBE design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perihematomal oedema</measure>
    <time_frame>7 days after ICH onset</time_frame>
    <description>Measured as Oedema Extension Distance (OED/EED)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events of special interest (AESI) and serious adverse events (SAE)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood brain barriere leakage</measure>
    <time_frame>7 days</time_frame>
    <description>Measured as Ktrans on DCE-MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of serum inflammatory markers</measure>
    <time_frame>7 days</time_frame>
    <description>IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal shift in functional outcome (comparing the intervention group to the controls), assessed with the modified Rankin Scale (mRS) at 3 months. This is a six point scale in which a score of 0 means no symptoms at all, a higher score means more impairment, and a score of 6 means the participant is dead.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Anakinra High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg i.v. loading dose, followed by continuous iv infusion with 2mg/kg/h over 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg s.c. loading dose, followed by subcuteanous administration of 100mg twice daily for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Anakinra treatment is started within 8 hours of symptom onset</description>
    <arm_group_label>Anakinra High dose</arm_group_label>
    <arm_group_label>Anakinra Low dose</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years;&#xD;
&#xD;
          2. Supratentorial non-traumatic ICH confirmed by CT, without a confirmed causative lesion&#xD;
             on admission CT-angiography (e.g. aneurysm, AVM, DAVF, cerebral venous sinus&#xD;
             thrombosis) or other known underlying lesion (e.g. tumour, cavernoma);&#xD;
&#xD;
          3. Minimal intracerebral haemorrhage volume of 10 mL;&#xD;
&#xD;
          4. Intervention can be started within 8 hours from symptoms onset;&#xD;
&#xD;
          5. Patient's or legal representative's informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe ICH, unlikely to survive the first 72 hours (defined as Glasgow Coma Scale&#xD;
             score &lt; 6 at time of consent);&#xD;
&#xD;
          2. Confirmed or suspected haemorrhagic transformation of an arterial or venous infarct;&#xD;
&#xD;
          3. Planned neurosurgical haematoma evacuation;&#xD;
&#xD;
          4. Severe infection at admission, requiring antibiotic treatment;&#xD;
&#xD;
          5. Known active tuberculosis or active hepatitis;&#xD;
&#xD;
          6. Use of immunosuppressive or immune-modulating therapy at admission (see 15.1 Appendix&#xD;
             A);&#xD;
&#xD;
          7. Neutropenia (Absolute Neutrophil Count (ANC) &lt;1.5 x 109/L );&#xD;
&#xD;
          8. Pre-stroke modified Rankin Scale score ≥ 3;&#xD;
&#xD;
          9. Pregnancy or breast-feeding;&#xD;
&#xD;
         10. Standard contraindications to MRI (see 15.2 Appendix B);&#xD;
&#xD;
         11. Known prior allergic reaction to gadolinium contrast or one of the constituents of its&#xD;
             solution for administration;&#xD;
&#xD;
         12. Known allergy to anakinra or other products that are produced by DNA technology using&#xD;
             the micro-organism E. coli;&#xD;
&#xD;
         13. Live vaccinations within the last 10 days prior to this ICH;&#xD;
&#xD;
         14. Severe renal impairment (eGFR &lt;30ml/min/1.73m)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Floris H.B.M Schreuder, MD PhD</last_name>
    <phone>+31650155755</phone>
    <email>floris.schreuder@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maaike P. Cliteur, MD</last_name>
    <phone>+31650155723</phone>
    <email>maaike.cliteur@radboudumc.nl</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

